Amp Volatility Score
Catalyst Info & Data Links
TITLE: Rezafungin for the Prevention of Fungal Infections - Phase 3
ClinicalTrial.gov (NCT04368559): Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (ReSPECT)
WHAT IS THE NEXT CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
11-05-2020 2020 Third Quarter Financial Results
05-20-2020 Cidara Therapeutics Doses First Patient In Pivotal Phase 3 Respect Trial Of Rezafungin For Prevention Of Invasive Fungal Disease In Patients Undergoing Allogeneic Blood And Marrow Transplantation
MECHANISM OF ACTION
Rezafungin is a novel echinocandin antifungal and the only once-weekly drug candidate being developed for the first-line treatment and prevention of serious invasive fungal infections. Rezafungin has a unique pharmacokinetic profile with a prolonged half-life and front-loaded plasma exposure which, in contrast to all other echinocandins, allows for once-weekly IV therapy for inpatient and outpatient use.
Updated by JM
CDTX, Cidara Therapeutics, Rezafungin, Prevention of Fungal Infections
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post